Key Highlights
- SkinBioTherapeutics Plc (LSE:SBTX) shares rose 8.33% on 30 September 2026, rebounding from recent lows.
- Interim chief executive Rachel Parsonage and acting chair Alyson Levett have agreed to make their roles permanent.
- Anita Slater joined as interim CFO in August, and talks on an additional independent non-executive director are at an advanced stage.
- The company released a pre-close trading update for the year ended 30 June 2026 on 22 September.
A Recovery Attempt After a Difficult Year
SkinBioTherapeutics Plc (LSE:SBTX) gained 8.33% on 30 September 2026, one of the stronger moves among London-listed healthcare small caps. The shares had fallen to around 5.75p on 23 September, near the bottom of a 52-week range of roughly 5p to 23p, on unusually heavy Volume of more than 110 million shares. Today's rise suggests that some investors see value after the sell-off. No fresh announcement was issued at the time of writing.
Why SkinBioTherapeutics Is in Focus
LSE:SBTX has faced a turbulent 2026. The life science company, which focuses on skin health and the gut-skin axis, saw its chief executive suspended and then resign in February amid a board investigation into his conduct. An independent investigation followed, and in April the shares were suspended from trading before being restored in early June.
Since then, the board has worked to rebuild governance. The latest step came on 22 September, when the company confirmed that Rachel Parsonage and Alyson Levett would continue as permanent chief executive and chair. With a new interim CFO in place and an independent non-executive appointment close, investors are watching whether Leadership stability can restore confidence.
Key Reasons Behind Today's 8.33% Rise
The first Factor is oversold conditions. After a steep fall and very high trading volumes around the trading update, the shares were sitting at multi-year lows, which attracted bargain hunters.
The second factor is leadership clarity. Making the interim roles permanent removes uncertainty about who is running the company and signals continuity in strategy.
The third factor is the commercial platform. SkinBioTherapeutics sells its AxisBiotix food supplements, which target skin conditions via the gut, through retail partners including Superdrug and online channels. It also has a cosmetic skincare Business and its proprietary SkinBiotix technology, originally developed from research at the University of Manchester. Some investors believe the Brand portfolio has value that the market is overlooking.
Trading Update Concerns
The 22 September pre-close update was not universally welcomed. Commentators noted it arrived later than usual, did not provide specific forward guidance, and confirmed the company remains loss-making and cash consuming. The company had also indicated it would provide a board update by mid-September, and that timetable slipped. These issues contributed to the sharp share price fall before today's rebound.
Earlier in 2026, management had reaffirmed full-year targets of £6.2 million in Revenue and £0.7 million of adjusted EBITDA for 2026, but the subsequent governance upheaval has made investors cautious about relying on those figures until audited results are published.
What Investors Are Watching
Key watch points include the audited full-year results, clarity on cash reserves and funding needs, details of any security or charges granted to lenders, confirmation of the new independent director, and sales momentum at AxisBiotix and retail partners.
Risks
SkinBioTherapeutics is loss-making and may need additional funding, which could dilute shareholders. Governance concerns have damaged credibility, and the shares remain volatile. Competition in skincare and supplements is intense.
Outlook
Today's 8.33% gain offers some relief, but LSE:SBTX needs to demonstrate stable governance and a credible path to profitability before a sustained recovery can take hold.






Please wait processing your request...